FibroGen Inc – Strategy, SWOT and Corporate Finance Report
- Pages: 48
- Published: July 2019
- Report Code: MLPH13844FSA
FibroGen Inc – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company
Key Highlights
FibroGen Inc (FibroGen) is a biopharmaceutical company that discovers, and develops medicines for the treatment of anemia, cancer, and fibrotic disease. The company is investigating its lead pipeline candidate: roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylases (HIF-PH), for the treatment of anemia related to chronic kidney disease (CKD) in dialysis-dependent (DD) patients; and in Phase II/III clinical trials for anemia associated with myelodysplastic syndromes. Its pipeline also comprises a biosynthetic corneal implant; and pamrevlumab, a human monoclonal antibody inhibitor of connective tissue growth factor (CTGF), in Phase III clinical studies for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer; and in Phase II clinical studies for the treatment of duchenne muscular dystrophy. FibroGen is headquartered in San Francisco, California, the US.
Scope
Detailed information on FibroGen Inc required for business and competitor intelligence needs
A study of the major internal and external factors affecting FibroGen Inc in the form of a SWOT analysis
An in-depth view of the business model of FibroGen Inc including a breakdown and examination of key business segments
News about FibroGen Inc, such as business expansion, restructuring, and contract wins
Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to buy
Gain understanding of FibroGen Inc and the factors that influence its strategies.Track strategic initiatives of the company and latest corporate news and actions.
Assess FibroGen Inc as a prospective partner, vendor or supplier.
Support sales activities by understanding your customers' businesses better.
Stay up to date on FibroGen Incs business structure, strategy and prospects.
Note: Some sections may be missing if data is unavailable for the company.
Companies mentioned
Vifor Pharma Ltd
Sandoz Inc
Pfizer Inc
Kyowa Hakko Kirin Co Ltd
Johnson & Johnson
Japan Tobacco Inc
GlaxoSmithKline Plc
F. Hoffmann-La Roche Ltd
Celgene Corp
Boehringer Ingelheim International GmbH
Bayer AG
Amgen Inc
Akebia Therapeutics Inc
Acceleron Pharma Inc
3SBio Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple report purchases.